Literature DB >> 29102694

KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma.

Jang Ho Cho1, Bo Mi Ku2, Jong-Mu Sun1, Se-Hoon Lee1, Jin Seok Ahn1, Keunchil Park1, Myung-Ju Ahn3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29102694     DOI： 10.1016/j.jtho.2017.10.014

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  15 in total

1.  Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.

Authors:  Félix Blanc-Durand; Raafat Alameddine; Anthony J Iafrate; Danh Tran-Thanh; Ying-Chun Lo; Normand Blais; Bertrand Routy; Mustapha Tehfé; Charles Leduc; Phillipe Romeo; Phillipe Stephenson; Marie Florescu
Journal:  Oncologist       Date:  2020-09-08

2.  An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology.

Authors:  Nicolas Piton; Marie-Delphine Lanic; Florent Marguet; Aude Lamy; France Blanchard; Florian Guisier; Mathieu Viennot; Mathieu Salaün; Luc Thiberville; Fabrice Jardin; Jean-Christophe Sabourin; Philippe Ruminy
Journal:  Lab Invest       Date:  2021-01-25       Impact factor: 5.662

Review 3.  Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.

Authors:  Fedor Moiseenko; Alexey Bogdanov; Vitaliy Egorenkov; Nikita Volkov; Vladimir Moiseyenko
Journal:  Curr Treat Options Oncol       Date:  2022-10-21

4.  Identification of a Novel EHBP1-MET Fusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib.

Authors:  Yiyi Yu; Qing Liu; Wei Li; Yueting Qu; Yihong Zhang; Tianshu Liu
Journal:  Oncologist       Date:  2020-10-12

Review 5.  Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.

Authors:  Olivier Bylicki; Nicolas Paleiron; Jean-Baptiste Assié; Christos Chouaïd
Journal:  Onco Targets Ther       Date:  2020-06-17       Impact factor: 4.147

Review 6.  Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.

Authors:  Kenichi Suda; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2020-12

7.  Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer.

Authors:  Michael J Fusco; Daryoush Saeed-Vafa; Estrella M Carballido; Theresa A Boyle; Mokenge Malafa; Kirsten L Blue; Jamie K Teer; Christine M Walko; Howard L McLeod; J Kevin Hicks; Martine Extermann; Jason B Fleming; Todd C Knepper; Dae Won Kim
Journal:  JCO Precis Oncol       Date:  2021-01-11

8.  Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer.

Authors:  Chien-Hung Gow; Yi-Nan Liu; Huei-Ying Li; Min-Shu Hsieh; Shih-Han Chang; Sheng-Ching Luo; Tzu-Hsiu Tsai; Pei-Lung Chen; Meng-Feng Tsai; Jin-Yuan Shih
Journal:  Neoplasia       Date:  2018-07-13       Impact factor: 5.715

9.  Autophagy Regulatory Genes MET and RIPK2 Play a Prognostic Role in Pancreatic Ductal Adenocarcinoma: A Bioinformatic Analysis Based on GEO and TCGA.

Authors:  Xingyu Li; Zhiqiang Li; Hongwei Zhu; Xiao Yu
Journal:  Biomed Res Int       Date:  2020-11-05       Impact factor: 3.411

10.  [Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].

Authors: 
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.